Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00758459 | Safety/Tolerability Study With AZD1236 in Chronic Obstructive Pulmonary Disease (COPD) Patients | PHASE2 | COMPLETED | 74 | — | — | Sep 1, 2008 | Mar 1, 2009 | Aug 19, 2011 | 14 | Bulgaria, Finland +3 |
| NCT00758706 | A Phase IIa Study Assessing the Effects of AZD1236 on Biomarkers in Chronic Obstructive Pulmonary Disease (COPD) Patients | PHASE2 | COMPLETED | 55 | — | — | Sep 1, 2008 | May 1, 2009 | Apr 16, 2015 | 10 | Denmark, Finland +2 |
Number of patients who had an Adverse Event
Ratio reflects Sputum Tumor Necrosis Factor alpha (TNF alpha) at week 6 value divide by baseline value. Baseline is geometric mean of Visit 2 (last value during run-in) and Visit 3 (Randomization).
Ratio reflects Sputum Total Cells at week 6 value divide by baseline value. Baseline is geometric mean of Visit 2 (last value during run-in) and Visit 3 (Randomization).
Ratio reflects Total Urine Desmosine at week 6 value divide by baseline value. Baseline is visit 3(Randomization) value.
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | PLACEBO_COMPARATOR | - |
| AZD1236 | EXPERIMENTAL | oral tablet, 75 mg, twice daily during 6 weeks |
| Placebo | PLACEBO_COMPARATOR | Dosing to match AZD1236 |
| Name | Type | Description |
|---|---|---|
| AZD1236 | DRUG | oral tablet, 75 mg, twice daily during 6 weeks |
| Placebo | DRUG | Dosing to match AZD1236 |
Inclusion Criteria: * Diagnosis of COPD for 1 month * Men or postmenopausal women * Spirometry values indicating reduced lung function * Smoking history equivalent to using 20 cigarettes a day for 10 years Exclusion Criteria: * Any current respiratory tract disorders other than COPD * Requirement...